Key Segments:
By Treatment Type
-
Anticoagulants
-
Catheter-Directed Therapies
-
Systemic Thrombolytics
-
Mechanical Thrombectomy
-
Others
By Drug Class
-
Direct Oral Anticoagulants
-
Heparins (LMWH & UFH)
-
Catheter-Based Devices
-
Thrombolytic Drugs
-
Others
By Patient Type
-
Acute Pulmonary Embolism
-
High-Risk Pulmonary Embolism
-
Cancer-Associated Pulmonary Embolism
-
Chronic Thromboembolic Disease
By End User
-
Hospitals
-
Cardiac & Vascular Centers
-
Ambulatory Surgical Centers
-
Specialty Clinics
-
Others
Regional Coverage:
North America
-
US
-
Canada
Europe
-
Germany
-
France
-
UK
-
Italy
-
Spain
-
Poland
-
Russia
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
ASEAN Countries
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Mexico
-
Colombia
-
Rest of Latin America
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Product X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market players
Frequently Asked Questions
The Pulmonary Embolism Market was valued at USD 2.87 Billion in 2025.
The market is anticipated to expand at a CAGR of 10.20% during the forecast period.
North America dominated the global Pulmonary Embolism Market in 2025 with a 41.00% revenue share.
Anticoagulants accounted for the largest revenue share of 48.00% in 2025.